Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
The Associated Press on MSN13d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback